Alliqua (ALQA)

Executive Summary

Alliqua BioMedical is a US-based developer and manufacturer of electron-beam cross-linked hydrogel products for the OEM market, targeting applications in wound care and skin care. The company's platform technology enables the delivery of active ingredients in prescription, over-the-counter, and other formats. Operating a GMP manufacturing facility in Langhorne, Pennsylvania, Alliqua is positioned to serve as a contract development and manufacturing organization (CDMO) for hydrogel-based products. Currently in Phase 1 stage, the company has no reported commercial products or FDA approvals and is operating as a private entity (ticker ALQA on OTC markets). With limited publicly available financials and no disclosed funding rounds, the company's valuation remains unclear, though its niche technology and early-stage status suggest significant upside potential if it can secure OEM partnerships or advance its own product pipeline.

Upcoming Catalysts (preview)

• 2026First OEM Partnership Announcement40% success
• 2027FDA 510(k) Clearance for Hydrogel Wound Dressing30% success
• 2026Completion of Facility Expansion or GMP Certification Update60% success